• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
Although chimeric antigen receptor (CAR) T cells can effectively fight B-lineage malignancies, disease relapse is common in patients after CAR, and the therapeutic efficacy for other tumors is very limited. These challenges may be solved by controlling the function of CAR-T cells through reasonable manipulation.
In 2010, Sonia Vallabh witnessed her 52-year-old mother develop a rapidly progressive, mysterious, and undiagnosed dementia, and soon died from it. A year later, she learned that her mother had a hereditary prion disease, fatal familial insomnia. After undergoing genetic testing, Sonia learned that she also carried the disease-causing gene mutation, which meant that she herself was likely to suffer from this prion disease. More importantly, this fatal disease usually develops around the age of 50 and quickly leads to death, and there is no cure.
In a new study, a research team from the Helmholtz Institute for RNA Infection Research and the University of Regensburg has provided new insights into how HIV-1, the virus that causes AIDS, cleverly hijacks cellular machinery to maintain its own survival. By dissecting the molecular interactions between the virus and its host, they identified a new strategy for HIV-1 to ensure its own replication while suppressing host cell defenses. The relevant research results were published online in the journal Nature Structural & Molecular Biology in January 2025, with the title "The translational landscape of HIV-1 infected cells reveals key gene regulatory principles".
Colorectal cancer is a type of cancer that begins in the colon (large intestine) or rectum, both of which are part of the digestive system. It usually starts as abnormal growths called polyps that form on the lining of the colon or rectum. Over time, some of these polyps may become cancerous if left untreated.
Estrogen receptor-α coactivator MED1 is overexpressed in 40%-60% of human breast cancers, and its high expression is directly associated with lower disease-free survival in patients receiving anti-estrogen therapy. However, the molecular mechanism of MED1 upregulation and activation in resistance to breast cancer therapy is still unclear to researchers.
Researchers at the Mayo Clinic published a research paper titled "Oncolytic cytomegaloviruses expressing EGFR-retargeted fusogenic glycoprotein complex and drug-controllable interleukin 12" in Cell Reports Medicine. This study developed an oncolytic human cytomegalovirus expressing an EGFR retargeting fusion gene glycoprotein complex and drug-controllable IL-12, and its significant anti-tumor effect was verified in glioblastoma (GBM) models.
Since the outbreak of the COVID-19 pandemic in late 2019, it has had a huge impact on health, society and economy around the world. As the virus continues to spread, we realize that the impact of COVID-19 infection goes far beyond the acute phase. Some patients still suffer from persistent symptoms weeks or even months after infection, a condition known as "Long COVID" or "Post-acute sequelae of COVID-19" (PASC).
Hemophilia is an X-linked recessive inherited bleeding disorder caused by genetic defects in coagulation factor VIII or coagulation factor IX. It is divided into two main types: hemophilia A (F VIII deficiency) and hemophilia B (F IX deficiency). In a new study, researchers from Christian Medical College in Vellore, India, and other research institutions found that lentiviral vectors can be successfully used to provide gene therapy for patients with severe hemophilia A. They provide a potential alternative to adeno-associated virus (AAV)-mediated gene therapy, solving the problem of excluding patients with pre-existing anti-AAV antibodies from gene therapy. The relevant research results were published online in the New England Journal of Medicine on December 9, 2024, with the title "Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A".
Recently, Belgian scientists published a research paper titled "Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity" in Nature Communications, a subsidiary of Nature. The study developed a Triplet lipid nanoparticles (LNP) therapy, in which intratumoral injection of LNP-delivered mRNA encoding IL-21, IL-7, and 4-1BBL can induce systemic anti-tumor immune response.
Recently, a review article discussing the therapeutic potential of natural killer (NK) cell biology was published in the journal Frontiers of Medicine. The article is titled "Intracellular checkpoints for NK cell cancer immunotherapy".
